Skip to content

Disposables and fluids

Concerted range of products

Fresenius Medical Care offers a wide range of individual disposables, pre-assembled kits and further products for CKRT - and in particular Ci‑Ca therapy - as well as for complementary therapies, such as plasma exchange, adsorbers for cytokine removal* and low-flow extracorporeal CO2 removal on the multiFiltratePRO.

All products are concerted to complement each other and facilitate easy delivery of effective treatments on the ICU.

*in selected countries

Ci‑Ca Dialysate

With our range of Ci‑Ca Dialysates, Ci‑Ca therapy can be tailored to the patients' needs. Ci‑Ca Dialysates are available in different potassium concentrations and with or without phosphate.

For more information on CKRT fluids available in your country, please contact your local Fresenius Medical Care representative.

CKRT filters and plasma filters

Ultraflux AV filters in CKRT

The Ultraflux AV filters10 contain a Fresenius Polysulfone membrane specially developed for CKRT. This membrane enables the elimination of smaller molecules such as uremic toxins and creatinine while plasma proteins like albumin, bigger molecules and cellular blood constituents are effectively retained.

Fresenius Medical Care's CKRT filters offer a number of advantages:

  • Appropriate for Ci‑Ca (RCA) and heparin anticoagulation
  • Steam sterilized
  • Up to 72 hours duration of use
  • A choice of different surface areas is available: Ultraflux AV 600 S (1.4 m2) and Ultraflux AV 1000 S (1.8 m2)

Ultraflux EMiC 2 for the removal of middle molecules

In addition to the conventional goals of CKRT, such as the control of the fluid status and the correction of electrolyte abnormalities, an enhanced reduction of IL-6, IL-8, and myoglobin has been demonstrated using EMiC 211 in comparison to Ultraflux AV 1000 S.1,2

The high‑permeability hemofilter Ultraflux EMiC 2 is used in Ci‑Ca CVVHD treatments. It can improve the removal of middle molecules exceeding the molecular weight of commonly known small-sized uremic toxins such as urea and creatinine, while retaining albumin.1‑5

Ultraflux EMiC 2 at a glance:

  • Clearance of middle molecules such as myoglobin or interleukin-62
  • Clearance has been demonstrated throughout citrate-anticoagulated CKRT for up to 72 hours3
  • Steep sieving coefficient curve3 closely mimics the physiological renal function
  • Substantially stable albumin levels1‑5

plasmaFlux for therapeutic plasma exchange

Our plasma filter plasmaFlux is used for indications such as autoimmune diseases, metabolic diseases, endogenous and exogenous intoxications.6

plasmaFlux separates the plasma from the blood cells through the Polysulfone membrane. plasmaFlux is a non-prefilled plasma filter. The surface layer inside of the Plasmasulfone capillary is surrounded and stabilized by a second homogeneous, fine-pored layer.The Polysulfone membrane enables substances to pass, including plasma proteins such as immunoglobulins (e.g. IgM of 940 kDa) and lipoproteins (e.g. LDL of 2500 kDa).


  • Simplified setup due to dry delivery of plasmaFlux P2 dry plasma filters - there is no need to stop priming to connect the plasma filter
  • Free passage of protein components even exceeding molecular weights of two million Dalton
  • Retaining blood cells

Low-flow CO2 removal with multiECCO2R

CKRT treatments can be combined with various forms of organ support such as gas exchangers, with limited additional invasiveness.7 Low-flow ECCO2R target blood flows can be achieved by efficient CKRT dialysis catheters, providing ease of use for CKRT system users.8

Fresenius Medical Care offers with the multiECCO2R* a product for low-flow CO2 removal:

  • Applicable for both multiFiltratePRO and multiFiltrate
  • Gas exchanger placed downstream of the hemofilter, but upstream of air detector9
  • Blood flow max. 500 ml/min if anticoagulation with heparin planned9
  • Blood flow max. 200 ml/min if Ci‑Ca anticoagulation used

* Legal manufacturer of multiECCO2R is EUROSETS S.r.l., Italy. Fresenius Medical Care Deutschland GmbH is a distributor of multiECCO2R in selected countries.

Related content

Our multi-modality team player.

Integrating Ci-Ca therapy in your clinical practice.

1 Eichhorn T et al. Blood Purif 2017; 44(4);260‑266

2 Weidhase L et al. Crit Care 2020; 24(1):644

3 Siebeck M et al. Ther Apher Dial 2018; 22(4):355‑364

4 Schmidt JJ et al. Blood Purif 2012; 34:246‑252

5 Weidhase L et al. PLoS ONE 2019; 14:e0215823

6 Instruction for Use, plasmaFlux P1/P2 dry, valid from 05/2020

7 Forster C et al. Crit Care 2013; 17:R154

Staudinger T. Perfusion 2020; 35:492-508

Instruction for use multiECCO2R, EU10306 - Rev. 04 2020/09/04

10 Instruction for use Ultraflux filters

11 Instruction for use EMiC2